Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Breast Neoplasms × trifluridine tipiracil drug combination × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 28 Colonic Neoplasms 7 Rectal Neoplasms 6 Neoplasm Metastasis 5 Stomach Neoplasms 3 Pancreatic Neoplasms 3 Gallbladder Neoplasms 3 Cholangiocarcinoma 3 Bile Duct Neoplasms 2 Adenocarcinoma 2 mCRC 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Small Cell Lung Carcinoma 1 Recurrence 1 Neutropenia 1 Neoplasms 1 Nasopharyngeal Carcinoma 1 Microsatellite-stable Colorectal Cancer 1 Lung Neoplasms 1 High-grade Extra Pulmonary Neuroendocrine Cancer 1 Gastric Cancer Adenocarcinoma Metastatic 1 First-line Treatment 1 Esophageal Squamous Cell Carcinoma 1 EFS 1 Dihydropyrimidine Dehydrogenase Deficiency 1 Clinical Stage III Gastric Cancer AJCC v8 1 Carcinoma 1 Breast Neoplasms 1 Biliary Tract Neoplasms 1

Interventions

Trastuzumab 266 Paclitaxel 228 Cyclophosphamide 223 Docetaxel 210 Capecitabine 162 Letrozole 143 Carboplatin 142 Fulvestrant 132 Doxorubicin 130 Bevacizumab 111 Anastrozole 92 Tamoxifen 88 Vinorelbine 83 exemestane 78 Gemcitabine 78 Epirubicin 78 Lapatinib 73 pertuzumab 71 Radiotherapy 65 Albumin-Bound Paclitaxel 65 pembrolizumab 63 palbociclib 57 eribulin 52 Cisplatin 50 130-nm albumin-bound paclitaxel 49 Everolimus 44 Taxes 39 Neoadjuvant Therapy 38 Goserelin 37 pyrotinib 34

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04489173 2025-09-19

TIBET

Borstkanker Onderzoek Groep

Phase 2 Active not recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡